CClinicalTrials.gg
Not yet recruitingNCT07425444Updated Feb 20, 2026

Attenuate the Stress Response in Laparoscopic Cholecystectomy

A Phase 4 interventional study of Dexmedetomidine and Fentanyl- midazolam in Laparoscopic Cholecystectomy Surgery, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Assiut University · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Aims of this study are to compare the effectiveness of dexmedetomidine versus fentanyl-midazolam in attenuating hemodynamic stress response during laparoscopic cholecystectomy (mainly HR). And to assess the recovery profile, the pain and opioid requirements, the sedation profile, and any adverse events during the first 24 hrs postoperatively

Read the detailed description

Induction of general anesthesia, direct laryngoscopy and tracheal intubation induce marked cardiovascular changes as well as autonomic reflex activity. Although the responses of blood pressure and heart rate are short lived, they might have detrimental effects in high-risk patients, especially those with cardiovascular disease (1). These cardiovascular responses are associated with increased plasma levels of catecholamines (2). The main reason for the intubation induced hypertension seems to be a release of noradrenaline and, to a lesser extent, of adrenaline. In addition, increased levels of adrenocorticotrophic hormone (ACTH) and dopamine have also been reported (3).

A variety of factors have been shown to have an effect on this stress response: the choice and dosages of premedication and induction agents (4), the skill of the operator, and probably the technique being used. Numerous studies have demonstrated an increased stress response during direct laryngoscopy, fibreoptic intubation and insertion of the laryngeal mask (5).

  • Dexmedetomidine is an Alpha 2 adrenoreceptors agonists may exert its analgesic effect through hyperpolarization of the non-adrenergic neurons which leads to depression of neuronal firing in the locus ceruleous together with suppression of the release of norepinephrine because of the stimulation of the central adrenergic receptors which produces a hypnotic effect without ventilatory depression (6).
  • Midazolam is the benzodiazepine with the shortest half-life. It produces sedation and amnesia by acting on the γ-aminobutyric acid type-A receptors; additionally, its combined application in peripheral nerve blocks can increase the convulsive threshold of local anesthetics. It should be noted that GABA enhanced in amplitude by midazolam resulting in inhabitation of projection neurons and antinociception (7).

Fentanyl citrate is an opioid strong analgesic that is particularly well suited for use in anesthesia because of its high potency, rapid onset and short duration of action, absence of emetic activity, and minimal hypotensive activity after intravenous administration. As with other morphine-like analgesics. (8).

Laparoscopic cholecystectomy has increasingly been accepted as the procedure of choice for treatment of symptomatic gallstones and chronic cholecystitis (9). Its role and its timing in the management of acute cholecystitis, however remain controversial. The potential hazard of severe complications as a result of distorted anatomy caused by acute inflammation is a major concern (10)

02

Conditions studied

  • Laparoscopic Cholecystectomy Surgery

Browse trials for

Keywords

  • stress response
03

In context

Fractures, Stress

168 studies on the registry are indexed under Fractures, Stress; 41 are open to participants now.

This study's planned enrollment of 50 is below the median of 66 across 134 interventional studies indexed under Fractures, Stress.

Browse Fractures, Stress studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18-65 years.
  • Both sexes.
  • American Society of Anesthesiology (ASA) physical status I - II.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to study drugs.
  • Uncontrolled, non-correctable comorbidities (hepatic, renal or cardiac such as hypertension \& Arrhythmia ).
  • History of psychiatric illness or substance abuse.
  • Pregnancy or lactation
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Dexmedetomidine Group

    Drug: Dexmedetomidine

  • Active comparator
    Fentanyl-Midazolam Group

    Drug: Fentanyl- midazolam

Interventions

  • DrugDexmedetomidine

    investigator will give Loading dose 1 mcg/kg IV over 10 min, followed by infusion 0.5 mcg/kg/h until pneumoperitoneum established

  • DrugFentanyl- midazolam

    Investigator will inject Fentanyl 2 mcg/kg IV + Midazolam 0.05 mg/kg IV before induction.

06

What researchers measure

Primary outcomes

  1. Hemodynamics

    Hemodynamics mainly HR

    Time frame: During procedure

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kum CK, Goh PM, Isaac JR, Tekant Y, Ngoi SS. Laparoscopic cholecystectomy for acute cholecystitis. Br J Surg. 1994 Nov;81(11):1651-4. doi: 10.1002/bjs.1800811130. PubMed 7827896 ↗
  • Bass EB, Pitt HA, Lillemoe KD. Cost-effectiveness of laparoscopic cholecystectomy versus open cholecystectomy. Am J Surg. 1993 Apr;165(4):466-71. doi: 10.1016/s0002-9610(05)80942-0. PubMed 8480883 ↗
  • GARDOCKI JF, YELNOSKY J. A STUDY OF SOME OF THE PHARMACOLOGIC ACTIONS OF FENTANYL CITRATE. Toxicol Appl Pharmacol. 1964 Jan;6:48-62. doi: 10.1016/0041-008x(64)90021-3. No abstract available. PubMed 14105897 ↗
  • Kohno T, Kumamoto E, Baba H, Ataka T, Okamoto M, Shimoji K, Yoshimura M. Actions of midazolam on GABAergic transmission in substantia gelatinosa neurons of adult rat spinal cord slices. Anesthesiology. 2000 Feb;92(2):507-15. doi: 10.1097/00000542-200002000-00034. PubMed 10691239 ↗
  • Kosugi T, Mizuta K, Fujita T, Nakashima M, Kumamoto E. High concentrations of dexmedetomidine inhibit compound action potentials in frog sciatic nerves without alpha(2) adrenoceptor activation. Br J Pharmacol. 2010 Aug;160(7):1662-76. doi: 10.1111/j.1476-5381.2010.00833.x. PubMed 20649570 ↗
  • Smith JE, King MJ, Yanny HF, Pottinger KA, Pomirska MB. Effect of fentanyl on the circulatory responses to orotracheal fibreoptic intubation. Anaesthesia. 1992 Jan;47(1):20-3. doi: 10.1111/j.1365-2044.1992.tb01946.x. PubMed 1536396 ↗
  • Bucx MJ, van Geel RT, Scheck PA, Stijnen T. Cardiovascular effects of forces applied during laryngoscopy. The importance of tracheal intubation. Anaesthesia. 1992 Dec;47(12):1029-33. doi: 10.1111/j.1365-2044.1992.tb04195.x. PubMed 1489023 ↗
  • Weatherill D, Spence AA. Anaesthesia and disorders of the adrenal cortex. Br J Anaesth. 1984 Jul;56(7):741-9. doi: 10.1093/bja/56.7.741. No abstract available. PubMed 6375706 ↗
  • Derbyshire DR, Chmielewski A, Fell D, Vater M, Achola K, Smith G. Plasma catecholamine responses to tracheal intubation. Br J Anaesth. 1983 Sep;55(9):855-60. doi: 10.1093/bja/55.9.855. PubMed 6615672 ↗
  • Siedlecki J. Disturbances in the function of cardiovascular system in patients following endotracheal intubation and attempts of their prevention by pharmacological bloackade of sympathetic system. Anaesth Resusc Intensive Ther. 1975 Apr-Jun;3(2):107-23. PubMed 1180371 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07425444
Lead sponsor
Assiut University
Responsible party
Anas Ahmed Abd Elmoaty (doctor, Assiut University) — Principal investigator
First posted
Feb 20, 2026
Start date
Feb 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Feb 20, 2026

Study contacts

Anas Ahmed Abd elmoaty, resident doctor
Contact
anasa1@yahoo.com
+201006318654
Obey mohamed elhassan Shaker Osman, prof
Contact
Obeywafa@hotmail.com
+201143311373

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion